FULGENT GENETICS INC (FLGT) Stock News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm

FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm

A Peek at Fulgent Genetics's Future Earnings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such...

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc

/PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces its...

Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 121.05% and 2.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: SDGR

Fulgent Reports First Quarter 2025 Financial Results

Earnings Scheduled For May 2, 2025

Mentions: BEP MG WT CI ...

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

Fulgent Genetics Revenue Tops Estimates

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

FLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fulgent Genetics (NASDAQ:FLGT) just reported results for the first quarter of 2...

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025

Fulgent Reports Third Quarter 2024 Financial Results

Fulgent to Participate in Upcoming Conferences

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

Fulgent Reports Second Quarter 2024 Financial Results

Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024

Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics

FLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024

FLGT stock results show that Fulgent Genetics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Fulgent Reports First Quarter 2024 Financial Results

Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results

Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024

Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing

/PRNewswire/ -- CooperSurgical®, a global leader in fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a...

Mentions: COO